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this result should be interpreted with cau-
tion because only 30 patients in the study
had EGFR-mutated tumors and the 95%
confidence intervals for the HRs were
wide (upper limit 1) and overlapping;
however taking account of this promising
data, bevacizumab combined with EGFR-
tyrosine kinase inhibitor is attractive for
patients with EGFR mutations and ran-
domized studies are warranted.
Young Hak Kim, MD, PhD
Michiaki Mishima, MD, PhD
Department of Respiratory Medicine
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The place of extra pleural pneu-
monectomy (EPP) in the treatment of
N0-1 epithelioïd mesothelioma with cu-
rative intent is still debatable. Posto-
perative hemithoracic radiotherapy has
been recommended, since the publica-
tion of Rusch in 2001. Nevertheless,
peritoneal or contralateral pleural recur-
rences are frequent in the literature.
We read with interest the article
by Rice et al.1 in the August issue of
the journal that the recommendations
of the International Association for the
Study of Lung Cancer and the Interna-
tional Mesothelioma Interest Group
concerning EPP state that “in cases
where the pericardium and/or dia-
phragm are not involved by tumor,
these structures may be left intact.” In
our consecutive series of 15 patients,
we preserved the pericardium and the
diaphragm to avoid peritoneal or
pericardial seeding of the tumor.2
Polyglactin woven mesh was used to
reinforce the denervated diaphragm to
lower it, open the pleural sac, and
facilitate radiotherapy. There were no
postoperative deaths. Preservation of
the diaphragm and pericardium seems
to facilitate the postoperative course
without increase of recurrences in
these areas.
For the last 4 years, we have rou-
tinely performed a laparoscopy, a con-
tralateral thoracoscopy, and a mediasti-
noscopy during the same anesthesia, 1
week before EPP. During this period, 10
laparoscopies were carried out and 3 peri-
toneal invasions were detected which ex-
cluded resection for those patients.
As stated by Chi et al.3 in the June
issue of the journal, local control re-
mains poor despite conventional adju-
vant hemithoracic radiotherapy. This
can be improved by the delivery of ad-
juvant intensity-modulated radiotherapy
and especially helical tomotherapy
which we adopted for the last five pa-
tients in our series.4
In our opinion, this current strat-
egy should minimize postoperative mor-
tality, local recurrences, and peritoneal
and contralateral pleural seeding.
We noted the disappointing results
following EPP in the small MARS fea-
sibility study,5 but in the EPP arm, 5
patients had no surgery, it was com-
pleted satisfactorily in only 16 of 24
patients, 4 patients died perioperatively,
and only 8 received conventional radio-
therapy, and it is too early to draw con-
clusions from this study.
Pierre Bonnette, MD
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